- Home
- CAG vs ROIV Comparison
CAG vs ROIV Comparison
Compare CAG & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAG
- ROIV
- Stock Information
- Founded
- CAG 1919
- ROIV 2014
- Country
- CAG United States
- ROIV United Kingdom
- Employees
- CAG N/A
- ROIV N/A
- Industry
- CAG Packaged Foods
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- CAG Consumer Staples
- ROIV Health Care
- Exchange
- CAG Nasdaq
- ROIV Nasdaq
- Market Cap
- CAG 9.3B
- ROIV 8.6B
- IPO Year
- CAG N/A
- ROIV N/A
- Fundamental
- Price
- CAG $17.16
- ROIV $18.82
- Analyst Decision
- CAG Hold
- ROIV Strong Buy
- Analyst Count
- CAG 11
- ROIV 8
- Target Price
- CAG $21.64
- ROIV $21.06
- AVG Volume (30 Days)
- CAG 11.3M
- ROIV 7.6M
- Earning Date
- CAG 12-18-2025
- ROIV 11-10-2025
- Dividend Yield
- CAG 8.05%
- ROIV N/A
- EPS Growth
- CAG 73.36
- ROIV N/A
- EPS
- CAG 1.77
- ROIV N/A
- Revenue
- CAG $11,450,500,000.00
- ROIV $23,233,000.00
- Revenue This Year
- CAG N/A
- ROIV N/A
- Revenue Next Year
- CAG N/A
- ROIV $320.50
- P/E Ratio
- CAG $9.82
- ROIV N/A
- Revenue Growth
- CAG N/A
- ROIV N/A
- 52 Week Low
- CAG $17.35
- ROIV $8.73
- 52 Week High
- CAG $29.86
- ROIV $18.96
- Technical
- Relative Strength Index (RSI)
- CAG 31.89
- ROIV 81.18
- Support Level
- CAG $18.26
- ROIV $17.89
- Resistance Level
- CAG $18.99
- ROIV $18.96
- Average True Range (ATR)
- CAG 0.39
- ROIV 0.50
- MACD
- CAG -0.12
- ROIV 0.06
- Stochastic Oscillator
- CAG 9.43
- ROIV 95.45
About CAG ConAgra Brands Inc.
Conagra Brands is a packaged food company that operates predominantly in the United States (91% of fiscal 2025 revenue). Most of its revenue comes from frozen food, including brands like Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Conagra also sells snacks, shelf-stable staples, and refrigerated food through brands like Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. The company primarily sells through the US retail channel, with just 9% of fiscal 2025 revenue coming from international markets and 9% from foodservice.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.